Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches

Abstract

Iron metabolism is intricately linked with the immune response, and disturbances in iron homeostasis are frequently observed in the context of inflammatory disorders. This review examines the molecular mechanisms regulating iron metabolism during inflammation, epidemiology, and clinical consequences of iron dysregulation in inflammatory conditions. It also explores diagnostic challenges, evidence-based management strategies, emerging therapies, and guideline recommendations, aiming to provide a comprehensive reference for healthcare professionals managing patients with inflammation-associated iron disorders.

Introduction

Iron is an essential element for various physiological processes, including oxygen transport, DNA synthesis, and cellular respiration. The regulation of iron homeostasis is a complex, tightly controlled process, particularly susceptible to disruption during states of inflammation. Inflammatory disorders, both acute and chronic, profoundly impact iron metabolism, leading to clinical manifestations ranging from anemia of inflammation (AI) to iron overload syndromes. Understanding the interplay between iron metabolism and inflammation is crucial for optimizing diagnosis and treatment in affected patients.

Epidemiology / Disease Burden

Anemia of inflammation is one of the most common forms of anemia worldwide, affecting up to 40% of patients with chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD), chronic infections, and malignancies. The prevalence of iron deficiency in these populations contributes significantly to morbidity, impaired quality of life, and increased healthcare utilization. Conversely, dysregulated iron handling may exacerbate oxidative stress and tissue damage, compounding the burden of inflammatory disorders.

Pathophysiology

The pathophysiology of iron metabolism in inflammatory states is predominantly mediated by the hepatic peptide hormone hepcidin. Inflammatory cytokines, particularly interleukin-6 (IL-6), upregulate hepcidin synthesis, leading to internalization and degradation of the iron exporter ferroportin on enterocytes and macrophages. Consequently, iron is sequestered within macrophages and hepatocytes, reducing its availability for erythropoiesis and contributing to functional iron deficiency. Additionally, chronic inflammation may impair erythropoietin response and erythroid progenitor function, further compounding anemia. The balance between iron sequestration as a defense mechanism against pathogens and the physiological need for iron in erythropoiesis highlights the evolutionary trade-off in host defense and tissue oxygenation.

Risk Factors

Risk factors for iron metabolism disturbances in inflammatory disorders include the underlying disease activity, duration of inflammation, comorbidities such as chronic kidney disease, nutritional deficiencies, gastrointestinal blood loss, and use of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs). Genetic predisposition, including mutations affecting hepcidin regulation or iron transport proteins, may also influence susceptibility to iron dysregulation.

Clinical Features

Clinical manifestations of disturbed iron metabolism in inflammatory disorders depend on the balance between iron deficiency and overload. Anemia of inflammation typically presents with fatigue, pallor, reduced exercise tolerance, and cognitive impairment. In chronic inflammatory states, patients may also demonstrate signs of underlying disease activity, such as arthralgia, gastrointestinal symptoms, or evidence of chronic infection. Rarely, iron overload due to repeated transfusions or genetic predisposition may manifest with hepatomegaly, skin pigmentation, and endocrinopathies.

Diagnosis

Diagnosing iron metabolism disturbances in the context of inflammation poses significant challenges. Traditional biochemical markers such as serum ferritin, transferrin saturation, and serum iron may be confounded by acute phase responses. Ferritin, an acute phase reactant, may be elevated despite underlying iron deficiency. Measurement of soluble transferrin receptor and hepcidin levels, as well as inflammatory markers (e.g., C-reactive protein), can aid in differentiating true iron deficiency from functional iron restriction. Bone marrow iron staining remains the gold standard but is rarely performed due to its invasive nature. A comprehensive diagnostic approach integrating clinical context, laboratory data, and disease activity is essential.

Treatment & Management

Management strategies for iron metabolism disturbances in inflammatory disorders must address both the underlying inflammation and iron deficiency. Effective control of disease activity using immunosuppressive or biologic agents may reduce hepcidin levels and improve iron availability. Oral or intravenous iron supplementation should be tailored to the individual, with intravenous iron preferred in cases of active inflammation or malabsorption. Erythropoiesis-stimulating agents may be considered in refractory cases, particularly in chronic kidney disease. Careful monitoring for iron overload and adverse effects is necessary, especially in patients requiring long-term transfusion support.

Recent Advances / Emerging Therapies

Recent advances in understanding the molecular regulation of iron homeostasis have led to the development of novel therapeutic agents targeting the hepcidin-ferroportin axis. Hepcidin antagonists, ferroportin stabilizers, and monoclonal antibodies against IL-6 are under investigation and show promise in restoring iron availability and alleviating anemia of inflammation. Additionally, newer intravenous iron formulations with improved safety profiles offer enhanced options for rapid iron repletion. Ongoing clinical trials are expected to further refine the therapeutic landscape in the coming years.

Guideline Recommendations

Current guidelines from major societies, including the World Health Organization (WHO) and the European Crohn’s and Colitis Organisation (ECCO), recommend a tailored approach to iron supplementation, with intravenous iron favored in active inflammatory states and oral iron considered in stable disease. Regular monitoring of iron indices and inflammatory markers is advised. Management of the underlying inflammation remains paramount, and the use of erythropoiesis-stimulating agents should be reserved for selected cases after careful risk-benefit assessment.

Conclusion

Iron metabolism is profoundly affected by inflammatory disorders, with significant implications for patient outcomes. A nuanced understanding of the molecular mechanisms, clinical consequences, and evidence-based treatment strategies is essential for optimizing care. Emerging therapies targeting key regulatory pathways hold promise for improving management of anemia and iron dysregulation in the context of inflammation. Continued research and guideline refinement will enhance the precision and effectiveness of interventions in this complex clinical landscape.